Does Aetna Cover Forteo (Teriparatide)? A Complete Insurance Guide

What Is Forteo and Why Does It Require Prior Authorization?

Forteo is a recombinant form of parathyroid hormone (PTH 1-34) approved by the FDA in November 2002 for postmenopausal women with osteoporosis at high fracture risk, men with primary or hypogonadal osteoporosis, and men and women with glucocorticoid-induced osteoporosis [1]. It works by stimulating new bone formation rather than simply slowing resorption, which distinguishes it mechanistically from bisphosphonates like alendronate or risedronate.

Because Forteo costs roughly $3,200 to $3,800 per month at list price, payers including Aetna require prior authorization (PA) before dispensing. PA exists to confirm the drug is medically necessary for a specific patient and that less expensive alternatives have been tried first.

The Osteosarcoma Black-Box Warning

The FDA mandates a black-box warning on teriparatide because high-dose lifetime exposure caused osteosarcoma in male Fischer 344 rats [2]. No causal link to human osteosarcoma has been established in post-marketing surveillance, but the warning creates an additional regulatory layer that insurers cite when requiring documentation.

Why Aetna Specifically Targets Specialty Anabolics

Aetna, like most large commercial payers, classifies anabolic bone agents (teriparatide, abaloparatide, romosozumab) as specialty medications. The American Association of Clinical Endocrinology (AACE) 2020 guidelines recommend anabolic agents as first-line therapy only in very high-risk patients, defined as those with a T-score at or below -3.0, multiple vertebral fractures, or prior hip fracture [3]. Aetna's PA criteria mirror this risk stratification closely.

Aetna's Coverage Criteria for Forteo

Aetna approves Forteo when specific clinical thresholds are documented in writing by the prescribing physician. Getting the criteria exactly right before submitting the PA is the single most important step.

Minimum Clinical Requirements

Most Aetna commercial plans require ALL of the following:

• A confirmed diagnosis of osteoporosis with a DXA T-score of -2.5 or below at the lumbar spine or femoral neck, OR a documented fragility fracture.
• Documentation of at least one 12-month trial of an FDA-approved bisphosphonate (alendronate, risedronate, ibandronate, or zoledronic acid) with inadequate response, defined as a new fracture or continued bone mineral density loss of 5% or more, OR a documented contraindication or serious adverse event (e.g., severe esophageal disease, atypical femur fracture, osteonecrosis of the jaw).
• A FRAX 10-year hip fracture probability of 3% or greater, OR a major osteoporotic fracture probability of 20% or greater, per the National Osteoporosis Foundation thresholds [4].
• Prescribing by or in consultation with an endocrinologist, rheumatologist, or other specialist with documented expertise in metabolic bone disease.

Medicare Advantage Plans

For Aetna Medicare Advantage enrollees, coverage of teriparatide falls under Part D (the prescription drug benefit). CMS requires that Part D formularies cover at least two drugs in each therapeutic category, and most Aetna MA plans list teriparatide on Tier 4 or Tier 5 [5]. The PA criteria under Medicare Advantage generally align with commercial criteria, but cost-sharing structures differ. Some low-income subsidy (LIS) enrollees pay $0 to $4 per fill.

Medicaid Managed Care via Aetna Better Health

Aetna administers Medicaid managed care in several states. State Medicaid programs set their own PA thresholds, which may be more or less restrictive than commercial criteria. Contact Aetna Better Health directly or ask your pharmacist to run a coverage check with your exact state-specific plan ID.

How to Submit a Prior Authorization for Forteo Through Aetna

A well-prepared PA submission cuts the average processing time from 14 days down to 3 to 5 business days for non-urgent requests.

Documents Your Prescriber Should Gather

Gather the following before submission:

1. The most recent DXA report with T-scores at all measured sites.
2. Radiology or clinical notes confirming any fragility fractures (spine X-ray, MRI, or CT report).
3. A printed bisphosphonate therapy history showing drug name, dose, dates, and reason for discontinuation or inadequate response.
4. FRAX calculation printout from the FRAX tool (Sheffield model) [6].
5. A letter of medical necessity on clinic letterhead that directly cites Aetna's clinical policy number (typically CPB 0422 for bone-metabolism agents, though policy numbers change annually).
6. Any labs supporting secondary causes of bone loss: 25-OH vitamin D, serum calcium, thyroid-stimulating hormone, complete metabolic panel.

Submission Channels

Aetna accepts PA requests by fax (physician office can submit via Aetna's NaviMedix portal or standard fax lines), by phone through the provider services line printed on the member's insurance card, or electronically through the Aetna provider portal at provider.aetna.com. Electronic submissions typically receive a determination fastest.

Timeline

Standard (non-urgent) PA decisions: up to 14 calendar days under most state regulations. Urgent or expedited PA: 72 hours. If Aetna has not responded within those windows, the request is considered approved by default in many states under state prompt-pay and utilization management laws.

What Does Forteo Cost With Aetna Insurance?

Even with approval, your out-of-pocket cost depends on your plan's tier structure, deductible status, and whether you have reached your out-of-pocket maximum.

Tier-Based Cost Sharing

| Plan type | Typical tier | Estimated monthly copay | |---|---|---| | Aetna commercial PPO (in-deductible) | Tier 4 specialty | $600, $1,200 | | Aetna commercial PPO (post-deductible) | Tier 4 specialty | $150, $400 | | Aetna Medicare Advantage | Tier 4 to 5 | $100, $420 during coverage gap | | Aetna Medicaid (state-dependent) | Preferred | $0, $10 |

These figures are estimates. Call the member services number on your card and ask specifically for the "specialty drug cost estimator" for teriparatide (NDC 00002-8815-01 for the branded pen).

Manufacturer Savings Programs

Eli Lilly's Forteo Savings Card reduces monthly cost-sharing to as low as $25 per month for commercially insured patients who meet income thresholds, up to a cap of $4,800 in annual savings [7]. Patients without insurance or with government insurance (Medicare, Medicaid) do not qualify for the commercial card but may apply to Lilly Cares Foundation for free drug. Call 1-800-545-5979 or visit Lilly's patient assistance portal.

Generic teriparatide (launched 2022 by Alvogen and others) is typically placed one tier lower than branded Forteo on Aetna formularies, and the savings card situation differs for generics. Ask your pharmacy explicitly whether the dispensed product is branded or generic.

What Happens If Aetna Denies Coverage?

A denial is not the end. The appeals process works for a meaningful percentage of patients who submit complete documentation.

Step 1: Understand the Denial Reason

Aetna must provide a written explanation of denial (an Explanation of Benefits or a separate denial letter). The most common reasons for Forteo denials are:

• Insufficient bisphosphonate trial duration (less than 12 months documented).
• Missing DXA within the past 24 months.
• FRAX score not calculated or not meeting threshold.
• Prescriber not identified as a specialist in metabolic bone disease.

Step 2: File an Internal Appeal

You or your physician can file a first-level internal appeal within 180 days of the denial date (check your specific plan documents, as some commercial plans allow only 60 days). Submit all missing documentation with a cover letter that explicitly references each denial criterion and provides the corrective evidence.

Step 3: Expedited External Review

If the internal appeal fails, you have the right to an Independent Medical Review (IMR) or External Review under the Affordable Care Act. External reviewers are independent of Aetna. Data from the Kaiser Family Foundation show that consumers win external appeals roughly 40% of the time for prescription drug denials across all payers [8].

Step 4: Exception Request for Non-Formulary Coverage

If teriparatide is not on your specific plan's formulary at all, a formulary exception request follows a similar path. The standard of evidence is the same: medical necessity that cannot be met by a covered alternative.

Covered Alternatives to Forteo on Aetna Formularies

If Forteo is denied or cost-prohibitive, several alternatives share FDA approval for osteoporosis and are typically covered at lower tiers on Aetna plans.

Bisphosphonates (First-Line)

Alendronate (generic) and risedronate (generic) are on virtually every Aetna formulary at Tier 1 or Tier 2, often with $0 to $15 copays. The Fracture Intervention Trial (FIT, N=2,027) demonstrated that alendronate reduced vertebral fracture risk by 47% over 3 years in postmenopausal women with prior vertebral fractures [9]. For patients who cannot tolerate oral bisphosphonates, zoledronic acid 5 mg IV once yearly (HORIZON Key Fracture Trial, N=7,765) reduced hip fracture risk by 41% and vertebral fracture risk by 70% versus placebo over 3 years [10].

Denosumab (Prolia)

Denosumab 60 mg subcutaneous every 6 months is a RANK ligand inhibitor with strong fracture efficacy. The FREEDOM trial (N=7,868) showed a 68% reduction in new vertebral fractures and a 40% reduction in hip fractures over 36 months versus placebo [11]. Aetna generally covers Prolia with PA, and it is typically one tier lower than Forteo.

Abaloparatide (Tymlos)

Abaloparatide is a PTHrP analog with a mechanism similar to teriparatide. The ACTIVE trial (N=2,463) showed a 43% reduction in new vertebral fractures and a 70% reduction in nonvertebral fractures versus placebo at 18 months [12]. Aetna's PA criteria for abaloparatide closely parallel those for teriparatide.

Romosozumab (Evenity)

Romosozumab 210 mg monthly (2 injections of 105 mg) for 12 months targets sclerostin and produces rapid gains in bone mineral density. The ARCH trial (N=4,093) compared romosozumab followed by alendronate to alendronate alone and found a 48% lower risk of new vertebral fracture at 24 months in the romosozumab group [13]. Aetna covers romosozumab but requires documented cardiovascular risk assessment because the ARCH trial showed a higher rate of serious cardiovascular events in the romosozumab arm.

Clinical Context: Who Actually Needs Forteo?

Understanding the clinical rationale helps you advocate for coverage more effectively and helps physicians write stronger letters of medical necessity.

Fracture Risk Stratification

The 2020 AACE/ACE Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis define three risk categories [3]:

• High risk: T-score between -2.5 and -3.0, no prior fracture. First-line: bisphosphonate or denosumab.
• Very high risk: T-score at or below -3.0, one or more vertebral fractures, or hip fracture history. First-line: anabolic therapy (teriparatide, abaloparatide, or romosozumab).
• Imminent fracture risk: recent fracture within the past 12 months. First-line: anabolic therapy followed by antiresorptive.

As the AACE guidelines state: "Patients at very high risk of fracture should be considered for initial therapy with an anabolic agent" [3]. This language directly supports PA requests for Forteo without a required bisphosphonate trial in very-high-risk patients.

Sequential Therapy Matters

Teriparatide builds bone mass most effectively when followed by an antiresorptive agent. A Cochrane systematic review (Murad MH et al.) found that stopping teriparatide without subsequent antiresorptive therapy leads to rapid bone loss within 12 months [14]. Your prescriber should document the planned sequential therapy (bisphosphonate or denosumab post-Forteo) in the PA request, as this demonstrates medical appropriateness and may satisfy Aetna's cost-effectiveness criteria.

Glucocorticoid-Induced Osteoporosis: A Special Case

Patients on chronic glucocorticoid therapy (prednisone 5 mg/day or higher for 3 months or longer) represent a distinct population. The American College of Rheumatology 2022 guideline on glucocorticoid-induced osteoporosis conditionally recommends teriparatide over oral bisphosphonates for high-risk patients on glucocorticoids [15]. For these patients, Aetna's PA criteria may not require a prior bisphosphonate trial if the ACR guideline preferring teriparatide is cited explicitly.

Practical Steps: A Timeline for Getting Forteo Covered

Getting from prescription to first injection typically takes 2 to 6 weeks. Here is a realistic sequence:

1. Week 1. Prescriber orders DXA if not done in the past 24 months and calculates FRAX score. Orders baseline 25-OH vitamin D, serum calcium, and renal function.
2. Week 1 to 2. Prescriber's office submits PA with complete documentation package. Pharmacy benefit manager (ExpressScripts or CVS Caremark, depending on your Aetna plan) processes the request.
3. Week 2 to 3. PA approved or denied. If denied, prescriber's office files immediate first-level appeal.
4. Week 3 to 4. Appeal resolved. If approved, specialty pharmacy (typically Accredo or CVS Specialty for Aetna) ships first 28-day supply.
5. Week 4 to 6. First injection administered. Patient receives training on self-injection technique (injection should be in thigh or abdomen, not administered while recumbent, to minimize orthostatic hypotension risk).

FAQs About Aetna Coverage for Forteo